Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (SHE:300534) — Market Cap & Net Worth
Market Cap & Net Worth: Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534)
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (SHE:300534) has a market capitalization of $555.31 Million (CN¥3.79 Billion) as of September 16, 2026. Listed on the SHE stock exchange, this China-based company holds position #11725 globally and #3322 in its home market, demonstrating a -7.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's stock price CN¥12.51 by its total outstanding shares 303345000 (303.35 Million). Also see 300534 total asset value for a full breakdown of the balance sheet.
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Market Cap History: 2016 to 2026
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's market capitalization history from 2016 to 2026. Data shows growth from $800.32 Million to $555.31 Million (8.46% CAGR). Also see Gansu Longshenrongfa Pharmaceutical Indu (300534) cash flow conversion for how efficiently the company converts equity into cash flow.
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Gansu Longshenrongfa Pharmaceutical Indu (300534) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.47x
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's market cap is 0.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.57x
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's market cap is 9.57 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $800.32 Million | $269.68 Million | $47.25 Million | 2.97x | 16.94x |
| 2017 | $440.00 Million | $269.59 Million | $17.11 Million | 1.63x | 25.71x |
| 2018 | $251.73 Million | $203.17 Million | $12.28 Million | 1.24x | 20.50x |
| 2019 | $262.25 Million | $239.00 Million | $12.78 Million | 1.10x | 20.52x |
| 2020 | $255.64 Million | $254.90 Million | $1.83 Million | 1.00x | 139.61x |
| 2021 | $649.92 Million | $287.81 Million | -$9.11 Million | 2.26x | N/A |
| 2022 | $391.63 Million | $799.68 Million | $38.79 Million | 0.49x | 10.10x |
| 2023 | $435.78 Million | $1.08 Billion | $61.65 Million | 0.40x | 7.07x |
| 2024 | $386.18 Million | $1.04 Billion | $25.80 Million | 0.37x | 14.97x |
| 2025 | $420.81 Million | $886.96 Million | $43.95 Million | 0.47x | 9.57x |
Competitor Companies of 300534 by Market Capitalization
Companies near Gansu Longshenrongfa Pharmaceutical Industry Co Ltd in the global market cap rankings as of September 16, 2026. Review tangible net worth ratio of Gansu Longshenrongfa Pharmaceutical Indu to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Gansu Longshenrongfa Pharmaceutical Industry Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's market cap moved from $800.32 Million to $ 555.31 Million, with a yearly change of 8.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥555.31 Million | +31.96% |
| 2025 | CN¥420.81 Million | +8.97% |
| 2024 | CN¥386.18 Million | -11.38% |
| 2023 | CN¥435.78 Million | +11.27% |
| 2022 | CN¥391.63 Million | -39.74% |
| 2021 | CN¥649.92 Million | +154.23% |
| 2020 | CN¥255.64 Million | -2.52% |
| 2019 | CN¥262.25 Million | +4.18% |
| 2018 | CN¥251.73 Million | -42.79% |
| 2017 | CN¥440.00 Million | -45.02% |
| 2016 | CN¥800.32 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $555.31 Million USD |
| MoneyControl | $555.31 Million USD |
| MarketWatch | $555.31 Million USD |
| marketcap.company | $555.31 Million USD |
| Reuters | $555.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gansu Longshenrongfa Pharmaceutical Industry Co Ltd
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD researches, develops, produces, and sells traditional Chinese medicines, medical devices, and health products in China and internationally. It is also involved in the cultivation, processing, and sales of chemical drugs and medicinal herbs, as well as pharmaceutical distribution, testing, and inspection services. The company was founded in 2002… Read more